Excited to share that MediZap was a proud vendor exhibitor at the APC Compounders on Capitol Hill event in Washington, DC! It was an incredible opportunity to connect with pharmacy compounders and engage with federal legislators on issues impacting our industry. We're committed to supporting the compounding community and advocating for practices that enhance patient care. A big thank you to the Alliance for Pharmacy Compounding for hosting this impactful event!
Shortage Drug Compounding: To address recent drug supply chain issues, we propose expanding the definition of drug shortages, extending compounding allowances for 503Bs, and enforcing stricter reporting requirements for drug manufacturers.
Concerns About FDA's Proposed Demonstrably Difficult to Compound (DDC) List: We are concerned that the FDA's proposal to add entire drug categories to the 503A DDC list may exceed its legal authority and could lead to restrictions on hormone and GLP-1 compounding.
GLP-1 Compounding: Separating Fact from Fiction: We aim to clarify misconceptions about GLP-1 compounding by highlighting the differences between legitimate compounding practices and counterfeits, urging legislators to consider accurate information.
Animal Drug Compounding from Bulk Substances: We advocate against FDA restrictions that limit veterinarians' ability to compound medications from bulk substances, hindering immediate treatment and increasing animal suffering.